.png)
IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP6 is produced by bone cells and is the major IGF-BP present in cerebrospinal fluid, and specifically inhibits IGF-II actions. IGF-BP6 has been shown to inhibit IGF-II-dependent cancers such as neuroblastoma, colon cancer and rhabdomyosarcoma. Recombinant human IGF-BP6 has a calculated mass of 22.6 kDa and consists of 213 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain. IGF-BP6 migrates at an apparent molecular weight of approximately 23.0-30.0 kDa by SDS-PAGE analysis under non-reducing conditions.
Product Specific Information
Storage: Reconstituted h-IGFBP-6 should be stored in working aliquots at 20°C.
For research Purposes Only. Not for use in diagnostic or therapeutic procedures.
| PROPERTIES | |
|---|---|
| Species | Human |
| Expression System |
High-5, Insect Cells |
| Molecular Weight | 322.3 kDa |
| Full Length | 240 amino acids |
| Purity |
≥98% by SDS-PAGE and HPLC Analyses |
| Form | Lyophilized |
| Endotoxin | <1 EU/µg |
| Activity | Determined by its ability to inhibit IGF-I or IGF-II induced proliferation of FDC-P1 cells. |
| Storage | -20°C |
